Global Migraine Market Report: 2016 Edition - New Report by Koncept Analytics

1
Global Migraine Market Report
----------------------------------------- 2016
View Report Details
2
View Report Details

• Executive Summary
• Migraine is a common neurovascular disorder that
  is characterized by throbbing headaches and is
  commonly associated with other neurological
  symptoms, such as nausea, vomiting, and painful
  sensitivity to lights and sounds. Migraines are
  thought to result from the activation and
  sensitization of sensory neurons that have nerve
  endings in meningeal blood vessels. Migraines can
  be episodic or chronic. Chronic Migraine (CM) and
  Episodic Migraine (EM) are both part of the
  spectrum of migraine disorders, but are distinct
  clinical entities. The onset of migraine is
  preceded by certain triggers, which can be unique
  for each migraine sufferer.
• Triptans and Ergots are among the most common
  drug options existing in the treatment market for
  migraine. The global migraine treatment market
  currently faces several unmet needs and is
  saturated with the availability of generic drugs.
  Several branded drugs are under development with
  safer and more effective profiles, given the vast
  opportunities existing in the market. The focus
  of upcoming drugs is to either cure migraine or
  to reduce the frequency to a level where patients
  can find tolerable relief.
• The migraine market is expected to acquire modest
  growth driven by launch of new therapies and
  increasing rate of drug treatment due to
  increasing female population and rising awareness
  among physicians and patients. The major growth
  drivers of the migraine market includes rising
  spending on medicines, growing female population,
  increasing cigarette consumption and healthcare
  expenditure. However, the growth of the market
  will also remain challenged by complications
  associated with Triptans, treatment limitations
  for patients with CV (Cardio Vascular) risk and
  increased preference for OTC (Over the Counter)
  medications.
• The report, Global Migraine Market analyzes the
  currently prevailing condition of the market
  along with its future scope of development. The
  specific market of the U.S. is being discussed in
  the report. The major trends, growth drivers as
  well as issues being faced by the industry are
  being presented in this report. The major players
  in the industry are being profiled, along with
  their key financials and strategies for growth.

3
Among several drug options existing in the
market, Triptans and Ergots are the most common
treatment options available for migraine
Global Migraine Drug Market by Value (2013-2020E)

• The overall market for migraine drug is estimated
  to have reached US.. billion in the year 2015,
  increasing from US.. billion in year 2013. The
  drug market for migraine is further expected to
  reach US.. billion and US.. billion in year
  2017 and 2020 respectively.
• Nearly, of the global migraine treatment
  market is estimated to have been made up of
  medications based on active substance called
  Triptans in year 2015. The second group which
  accounted for nearly comprises medications
  based on Dihydroergotamine (DHE).
• In 2015, nearly .. share of the therapeutic
  Botulinum toxin market represented treatment of
  chronic migraine followed by cervical dystonia
  and overactive bladder holding and share
  respectively.

Global Migraine Drug Market by Category (2015E)
Global Therapeutic Botulinum Toxin Market by
Indication (2015)
4
The driving forces for growth of Migraine
market includes several innovations in medication
delivery, increased level of awareness of
migraine among doctors and patients combined with
innovation in delivery of clinically proven
marketed medications
The U.S. Total Migraine Population (2015-2022E)

• The U.S. migraine population is expected to reach
  million by the end of year 2022, increasing
  from million in 2015, on account of rising
  awareness among patients physicians and
  increasing migraine prevalence.
• Of .. million migraine population in the U.S.,
  nearly .. million (..) cases got diagnosed
  followed by nearly .. million (..) undiagnosed
  cases. Out of the million diagnosed cases,
  nearly million (..) cases were for prevention,
  while rest .. million (..) cases were not for
  prevention.
• Of the total candidates for prevention therapy in
  the U.S. in year 2015, nearly .. of the
  candidates were treated by neurologists. However,
  nearly .. of the prevention candidates got
  primary care treatment for the given year.

The U.S. Migraine Population by Diagnosis (2015E)
The U.S. Preventive Migraine Treatment by
Specialty (2015)
5
The U.S. migraine treatment market currently
faces several unmet needs. The current treatment
patterns necessitate introduction of new
therapies that are safer and more effective,
compared to currently available therapies
The U.S. Migraine Population with CV Risk Factors
(2015-2022E)

• In 2015, nearly .. or .. million patients of the
  total migraine patients in the U.S. had
  cardiovascular risk factors. Triptans were
  contraindicated in approximately .., or ..
  million patients. In addition, another .. of the
  migraine patients were at a risk for silent
  myocardial ischemia for the given year.
• Among the treated adult migraine patients in the
  U.S., nearly .. patients received Triptans
  during 2014. Of the .. Triptans treated
  population nearly .. were treated from Triptans
  only, .. from combination of Triptans
  Prophylaxis and .. with Triptans other acute
  classes.
• The prescription volume for acute migraine in the
  U.S. reached million in the year 2015, with as
  estimation of reaching million prescriptions by
  the end of year 2025.

The U.S. Acute Migraine Treated Population by
Drug Type (2014)
The U.S. Acute Migraine Prescription Volume
(2015-2025E)
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Migraine Market . To know more about this report
or for any customized research requirement,
please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com